Ac t i o n | 30 Jul 2026 23:45:30 ET │ 12 pages PTC Therapeutics Inc (PTCT.O) 2Q Takeaways & Model Update CITI'S TAKE Highlights from PTC's 2Q call continue to underscore solid Sephience growth dynamics in the US and growing momentum ex-US as it becomes a greater overall contributor into year-end. From here, we see a clear setup to Sephience outperforming trailing 2H estimates (implying 8.5% sequential growth 3Q/4Q) on expanded patient volume and stable pricing with the bulk of HTAs ongoing (i.e. the start ...